Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Southern Europe has been experiencing significant growth in recent years.
Customer preferences: Patients in Southern Europe are increasingly seeking personalized treatment options, leading to a rise in demand for targeted therapies. In addition, there is a growing preference for oral medications over traditional intravenous treatments, as they offer greater convenience and flexibility.
Trends in the market: One of the key trends in the Oncology Drugs market in Southern Europe is the increasing use of immunotherapies. These treatments work by stimulating the body's immune system to fight cancer cells, and have shown promising results in a number of different cancer types. Another trend is the rise of biosimilars, which are lower-cost versions of biologic drugs that have already been approved by regulatory authorities. As patents for many biologic drugs expire, biosimilars are becoming an increasingly important part of the Oncology Drugs market in Southern Europe.
Local special circumstances: Southern Europe has a relatively high incidence of certain types of cancer, such as lung cancer and breast cancer. This has led to a greater focus on developing effective treatments for these cancers, and has also contributed to the growth of the Oncology Drugs market in the region. In addition, Southern Europe has a well-established healthcare system, which has helped to ensure that patients have access to the latest treatments and technologies.
Underlying macroeconomic factors: The Oncology Drugs market in Southern Europe is being driven by a number of macroeconomic factors, including increasing investment in healthcare and rising levels of disposable income. In addition, the aging population in many Southern European countries has led to a higher incidence of cancer, which has contributed to the growth of the market. Finally, regulatory reforms in the region have helped to streamline the drug approval process, allowing new treatments to reach patients more quickly.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
